初诊老年多发性骨髓瘤患者研究进展：第19届欧洲血液学会年会报道  

Advances in elderly patients with newly diagnosed multiple myeloma from the 19th European Hematology Association Annual Congress

作　　者：朱婉秋[1] 陈文明[1] 

机构地区：[1]首都医科大学附属北京朝阳医院血液科,100020

出　　处：《白血病．淋巴瘤》2014年第7期390-392,共3页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81172252）

摘　　要：随着新的靶向骨髓瘤药物的应用,初诊老年多发性骨髓瘤（multiple myeloma,MM）患者的中位生存期从30个月延长至60个月,但具有一些高危预后因素的老年患者临床结果仍欠佳.文章结合第19届欧洲血液学会年会相关报道,从标准治疗方案、治疗方式、预后因素三个方面对初诊老年MM患者的研究进展作一介绍.As the introduction of novel agents, the median overall survival of elderly newly diagnosed multiple myeloma patients has increased roughly from 30 to 60 months. But patients with high risk prognostic features still have a poor clinical outcome. This paper which combined the 19th annual congress of the European Hematology Association （EHA） reviews the advances in elderly patients with newly diagnosed multiple myeloma, including standard of care, the way to treatment and prognostic factors.

关 键 词：多发性骨髓瘤 治疗 预后 

分 类 号：R733.3[医药卫生—肿瘤]